These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989 [TBL] [Abstract][Full Text] [Related]
5. An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia. Handgretinger R; Mezger M Expert Opin Biol Ther; 2024 Sep; 24(9):883-888. PubMed ID: 39222044 [TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 Editing of the Sharma A; Boelens JJ; Cancio M; Hankins JS; Bhad P; Azizy M; Lewandowski A; Zhao X; Chitnis S; Peddinti R; Zheng Y; Kapoor N; Ciceri F; Maclachlan T; Yang Y; Liu Y; Yuan J; Naumann U; Yu VWC; Stevenson SC; De Vita S; LaBelle JL N Engl J Med; 2023 Aug; 389(9):820-832. PubMed ID: 37646679 [TBL] [Abstract][Full Text] [Related]
7. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226 [TBL] [Abstract][Full Text] [Related]
8. Exagamglogene Autotemcel: First Approval. Hoy SM Mol Diagn Ther; 2024 Mar; 28(2):133-139. PubMed ID: 38228954 [TBL] [Abstract][Full Text] [Related]
9. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia. Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644 [TBL] [Abstract][Full Text] [Related]
10. Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin. Ravi NS; Wienert B; Wyman SK; Bell HW; George A; Mahalingam G; Vu JT; Prasad K; Bandlamudi BP; Devaraju N; Rajendiran V; Syedbasha N; Pai AA; Nakamura Y; Kurita R; Narayanasamy M; Balasubramanian P; Thangavel S; Marepally S; Velayudhan SR; Srivastava A; DeWitt MA; Crossley M; Corn JE; Mohankumar KM Elife; 2022 Feb; 11():. PubMed ID: 35147495 [TBL] [Abstract][Full Text] [Related]
11. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β Fu B; Liao J; Chen S; Li W; Wang Q; Hu J; Yang F; Hsiao S; Jiang Y; Wang L; Chen F; Zhang Y; Wang X; Li D; Liu M; Wu Y Nat Med; 2022 Aug; 28(8):1573-1580. PubMed ID: 35922667 [TBL] [Abstract][Full Text] [Related]
13. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models. Demirci S; Khan MBN; Hinojosa G; Le A; Leonard A; Essawi K; Gudmundsdottir B; Liu X; Zeng J; Inam Z; Chu R; Uchida N; Araki D; London E; Butt H; Maitland SA; Bauer DE; Wolfe SA; Larochelle A; Tisdale JF Cytotherapy; 2024 Jun; 26(6):641-648. PubMed ID: 38506770 [TBL] [Abstract][Full Text] [Related]
14. Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia. Parums DV Med Sci Monit; 2024 Mar; 30():e944204. PubMed ID: 38425279 [TBL] [Abstract][Full Text] [Related]
15. Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia. Ma SP; Gao XX; Zhou GQ; Zhang HK; Yang JM; Wang WJ; Song XM; Chen HY; Lu DR Gene; 2022 Apr; 820():146289. PubMed ID: 35143940 [TBL] [Abstract][Full Text] [Related]
16. Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34 Katta V; O'Keefe K; Li Y; Mayuranathan T; Lazzarotto CR; Wood RK; Levine RM; Powers A; Mayberry K; Manquen G; Yao Y; Zhang J; Jang Y; Nimmagadda N; Dempsey EA; Lee G; Uchida N; Cheng Y; Fazio F; Lockey T; Meagher M; Sharma A; Tisdale JF; Zhou S; Yen JS; Weiss MJ; Tsai SQ Mol Ther; 2024 Oct; 32(10):3433-3452. PubMed ID: 39086133 [TBL] [Abstract][Full Text] [Related]
17. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major. Lüftinger R; Zubarovskaya N; Galimard JE; Cseh A; Salzer E; Locatelli F; Algeri M; Yesilipek A; de la Fuente J; Isgrò A; Alseraihy A; Angelucci E; Smiers FJ; La La Nasa G; Zecca M; Fisgin T; Unal E; Kleinschmidt K; Peters C; Lankester A; Corbacioglu S; Ann Hematol; 2022 Mar; 101(3):655-665. PubMed ID: 34999929 [TBL] [Abstract][Full Text] [Related]
18. Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia. Thuret I; Ruggeri A; Angelucci E; Chabannon C Stem Cells Transl Med; 2022 Apr; 11(4):407-414. PubMed ID: 35267028 [TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia. Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic base editing of human hematopoietic stem cells. Zeng J; Wu Y; Ren C; Bonanno J; Shen AH; Shea D; Gehrke JM; Clement K; Luk K; Yao Q; Kim R; Wolfe SA; Manis JP; Pinello L; Joung JK; Bauer DE Nat Med; 2020 Apr; 26(4):535-541. PubMed ID: 32284612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]